What if paralysis 👨🦽 wasn’t permanent - or at least not untreatable?
What if we could deliver regenerative signals to the central nervous system… through a simple intranasal spray?
In our latest @ProgressPotent1, @liorshal (CEO of @NBiologic) breaks down the science behind ExoPTEN - an exosome-based therapy designed to deliver siRNA and temporarily silence the PTEN signaling pathway, one of the nervous system’s key “brakes” on regeneration. 🚀
In preclinical models, this approach has shown something rarely seen in this field: meaningful functional recovery after severe spinal cord injury.
We explore:
- Why the central nervous system struggles to regenerate;
- Whether exosomes can finally solve the delivery problem;
- Dr. Shaltiel’s journey-from ion channel biophysics to leading one of the more ambitious bets in neuroregeneration;
Watch here: https://t.co/CAf2T5b0YI
#Biotech #Neuroscience #SpinalCordInjury #RegenerativeMedicine #Exosomes #Neuroregeneration #GeneSilencing #FutureOfMedicine #HealthTech #Longevity @russopartners@HebrewU
🔬✨ In biotech, IP is a great moat!!
Proud that we received a U.S. Patent Allowance for our proprietary process of producing exosomes!
https://t.co/OeqpkPUKpl
The Science Behind the Magic ✨
Drug Discovery World took a deep look at the mechanisms behind our exosome therapy, designed to help damaged nerves regenerate, rewire and recover, and what it takes to translate to clinical .
Read more: https://t.co/R6O6eXJRPy
https://t.co/cen2pdcBA3
Large scale preclinical testing to be performed on ExoPTEN.. A step closer to clinical trials and added hope for patients with acute spinal cord injuries....
#ExoTherapy#Nanodrugs#OrphanDrugs#Medicalinnovation
https://t.co/9Ck25nQwfe
Read all about ExoPTEN - an innovative therapy under development by NurExone for patients with acute spinal cord injuries!
#Unlockinghope#MedicalInnovation
Professor Shulamit Levenberg, of the Technion - Israel Institute of Technology, reflects on the beginning of NurExone and its exosome-based therapy for spinal cord regeneration.
https://t.co/gl7DYVSqpM
Compliments to our CEO Dr. Lior Shaltiel, PhD as per his recent nomination as co-chair of the Israeli organization for engineering, architecture and technological industries - the Med-Tech.
https://t.co/LewUdd2SoH
#biotechnology#israelitech#engineering#biotechorganization
I mark personally a significant milestone as NurExone Biologic celebrates its one-year anniversary as a public traded company! 🚀 🎉
I extend our heartfelt thanks to our incredible team, supportive shareholders, and valued stakeholders for their crucial…https://t.co/AM9SARBDv1
@NBiologic is publicly traded for 1 year 👏
We are pleased to share here some of our scientific and business' achievements.
Looking forward to the success ahead of us! 🥂
NurExone Biologic reports additional positive preclinical trial outcomes with ExoPTEN: 75% of paralyzed rats show recovery after Acute Spinal Cord Injury study!
Read the full PR here:
https://t.co/bRdcBa57OR
This Wednesday (Feb 15th), I will attend the OurCrowd summit in Jerusalem.
Happy to meet and discuss with individuals and potential Investors who are interesting in NurExone Biologic's unique therapy and technology platform to trea…https://t.co/1c4JgFLwTS https://t.co/8SSobdl68O
Introduction to our International MBA programs at The Hebrew University Business School
Date: Sunday, January 29, 2023
Time: 6:00PM JLM
Register here: https://t.co/rXyx6lpTfB https://t.co/Zl4YIZ2sTI